VEGFA and glioblastoma: Results from multiple independent cohorts showed that ADC-low (ADCL), the mean value of the lower peak of a double-gaussian mixed model fit to the ADC histogram extracted from the contrast-enhancing tumor regions, is a predictor of survival in patients with recurrent glioblastomas treated with a variety of anti-VEGF agents [7-14].